Various medical syringes before preparation.

In 2018, hyaluronic acid dermal fillers gained significant popularity, with approximately 810,240 treatments performed that year. Notably, they ranked as the second most popular non-surgical procedure, with a surge of 54% and expenditure on these aesthetic treatments reaching around $544 million.

In aesthetic medicine, dermal fillers have become a preferred option for enhancing beauty. Many seek swift solutions for skin or facial concerns like dark circles, wrinkles, or fine lines. Medical practitioners frequently evaluate the merits of fillers like Dermalax versus Juvederm, considering their specialized injectables designed to address each patient’s unique needs. 

This article focuses on Dermalax vs Juvederm, their compositions, mechanisms of action, clinical efficacy, and safety profiles.

Key Takeaways

  • Dermalax and Juvederm are HA-based dermal fillers offering various formulations and injections for specific areas.
  • Dermalax’s HA acts as a moisture magnet, attracting and retaining water within the skin.
  • Once injected, Juvederm binds with water molecules, filling wrinkles and enhancing facial contours.
  • With Juvederm’s approval, most medical professionals may prefer these HA injectables, thanks to the safety and efficacy of these injectables, which the US FDA ensures.
  • Understanding the practical considerations of these injectable dermal fillers can lead to patient education and informed decisions.

About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. Order Dermalax online at Medica Depot today! Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.

Introduction to Dermalax and Juvederm

A medical professional administering a facial injection into a patient's eye region.

Dermal fillers, often known as soft-tissue fillers, offer non-surgical options for individuals seeking aesthetic enhancements. They can plump lips, improve the appearance of tear troughs and other facial aging signs, and enhance contours. Hyaluronic acid (HA) dermal fillers are the most popular for their safety and versatility.

Dermalax and Juvederm are HA-based dermal fillers offering various formulations and injections for specific areas. Across Korea and Allergan are the companies behind these injectables that can restore volume, smooth wrinkles, and enhance facial contours.

Selecting the most appropriate dermal filler requires considering factors like immediate results, longevity of effects, ingredients, and mechanism of action. Patients must consult medical professionals for a tailored treatment plan to address specific concerns and desired outcomes.

Composition and Mechanism of Action

Dermalax injectable fillers have four variations: Dermalax Deep Plus, Deep, Plus, and Implant Plus. Despite their differences, these injections contain pure hyaluronic acid cross-linked using advanced technology. The HA concentration ranges from 20mg/ml to 24mg/ml, depending on the product. Moreover, Dermalax products with ‘Plus’ contain 0.3% lidocaine to ensure patient comfort during injection.

Dermalax’s HA acts as a moisture magnet, attracting and retaining water within the skin. This property optimizes skin hydration, promoting elasticity and suppleness. Additionally, Dermalax offers volumizing and facial contouring to the treated area and can give satisfying and impressive results using a minimally invasive and non-surgical treatment.

On the other hand, Juvederm dermal fillers have six injectables: Volux XC, Voluma XC, Vollure XC, Ultra Plus XC, Ultra XC, and Volbella XC. Juvederm injections utilize Vycross Technology to cross-link the HA molecules to create a smooth gel filler. Furthermore, each injection contains a small quantity of lidocaine to decrease injection site pain.

Once injected, Juvederm binds with water molecules, filling wrinkles and enhancing facial contours. The treatment adds volume and smoothness to the treated region, improving skin texture and delivering natural-looking and long-lasting results.

Clinical Efficacy

Medical experts working in a laboratory.

Clinical studies have confirmed the effectiveness of both Dermalax and Juvederm in addressing facial concerns. While both demonstrate safety and efficacy, it’s worth noting that Juvederm received the US Food and Drug Administration approval, while Dermalax has yet to find its approval.

Despite this, a clinical study demonstrated that Dermalax Plus is comparable in effectiveness to Restylane Sub-Q hyaluronic acid filler in addressing severe nasolabial folds over 24 weeks. Dermalax Plus also offers lesser discomfort and pain due to its lidocaine component than Restylane Sub-Q.

On the other hand, after more than nine months, 75% of patients treated with Juvederm Ultra and 81% of those treated with Juvederm Ultra Plus maintained a clinically significant correction in their nasolabial folds (NLFs). Remarkably, 78% of NLFs treated with Juvederm Ultra Plus continued to show clinically significant improvement beyond one year.

Despite lacking US FDA approval, Dermalax has undergone meticulous clinical testing, confirming its safety and effectiveness for skin concerns. However, with Juvederm’s FDA approval, most medical professionals may prefer these HA injectables in terms of safety and efficacy.

Safety Profiles

Individuals must have thorough consultations with their aesthetic providers before undergoing any treatment. This allows providers to develop personalized treatment plans, discuss the entire procedure, and provide detailed information about potential Juvederm or Dermalax side effects.

Both Dermalax and Juvederm have established safety profiles. Patients may experience typical side effects related to the injection sites, which usually resolve within a few days or weeks. However, if any side effects persist, seeking medical attention is advisable for proper management.

  • Dermalax Side Effects:  Redness, swelling, bruising, and tenderness at the injection site.
  • Juvederm Side Effects: Rredness, swelling, pain, and tenderness at the injection site.

Practical Considerations

A medical professional marking the injection sites for the patient's treatment.

Understanding the practical considerations of these injectable dermal fillers can lead to patient education and informed decisions. Medical professionals can help patients with the treatment procedure and determine which filler suits individuals’ needs and goals. These are the treatment areas suitable for both injectables.

  • Dermalax: Facial regions and concerns, such as wrinkles, fine lines, and folds. It can address volumizing and contouring effects in the cheeks, chin, nose, forehead, and lips.
  • Juvederm: Facial region and concerns, such as aging signs. It addresses various areas, such as jawline, cheeks, chin, lips, and under eyes.

Meanwhile, Juvederm results may last one year to two years, depending on the formula used and the area treated. Dermalax injections can deliver outcomes from six months to a year, based on individual factors, treatment area, and injection used. Proper post-treatment care and lifestyle can help maintain optimal outcomes.

Regular follow-up appointments and maintenance touch-ups for Dermalax and Juvederm injectables can help patients achieve their desired goals and increase patient satisfaction. According to RealSelf, Juvederm received an average of 90% patient ratings as worth it treatment. However, Dermalax has no rating yet on the review platform.

Conclusion

Comparing Dermalax vs Juvederm provides valuable insights for medical professionals and individuals seeking dermal filler treatments. Dermalax and Juvederm offer unique compositions, mechanisms of action, and clinical efficacy, catering to diverse patient needs. The decision between Dermalax and Juvederm should be based on individualized treatment plans, considering factors such as immediate results, longevity of effects, and patient satisfaction.

While only Juvederm has received US FDA approval, Dermalax has demonstrated comparable effectiveness and safety through rigorous clinical testing. Consulting with medical professionals is crucial for determining the most suitable dermal filler to address specific aesthetic goals and concerns, helping in informed decision-making in aesthetic medicine.

FAQs

1. What are the key differences between Dermalax vs Juvederm dermal fillers?

Dermalax and Juvederm differ in their compositions, mechanisms of action, clinical efficacy, and safety profiles. Dermalax has variations such as Deep Plus, Deep, Plus, and Implant Plus. In contrast, Juvederm has injectables like Volux XC, Voluma XC, Vollure XC, Ultra Plus XC, Ultra XC, and Volbella XC.

2. Have these dermal fillers received the US Food and Drug Administration approval?

It’s worth noting that Juvederm’s collection of dermal fillers has received approval from the US FDA, while Dermalax has yet to receive this approval.

3. What are the primary considerations when choosing between Dermalax and Juvederm?

When choosing between Dermalax and Juvederm, factors such as immediate results, longevity of effects, ingredients, and mechanism of action should be considered. Patients should consult medical professionals for a tailored treatment plan based on specific concerns and desired outcomes.

Require assistance or custom offers?

Our sales representatives are here to help.

BOOK A MEETING

References

  1. The Aesthetic Society. (n.d.). The Aesthetic Society releases annual statistics revealing significant increases in face, breast, and body in 2021. https://www.theaestheticsociety.org/media/press-releases/aesthetic-society-releases-annual-statistics-revealing-significant-increases
  2. Pinsky, M. A., Thomas, J. A., Murphy, D. K., Walker, P. S., & Juvéderm vs. Zyplast Nasolabial Fold Study Group (2008). Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surgery Journal, 28(1), 17–23. https://doi.org/10.1016/j.asj.2007.09.005